Last reviewed · How we verify
NCT04614753
Dealcoholized Muscadine Wine and Skin Health in Women
NA trial testing Dealcoholized Muscadine Wine in Skin Health in 20 participants. Completed in 7 October 2024.
7 October 2024
Quick facts
| Lead sponsor | University of Florida |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 10 October 2020 |
| Primary completion | 7 October 2024 |
| Estimated completion | 7 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dealcoholized Muscadine Wine
- Control Beverage
Conditions studied
- Skin Health — all drugs for Skin Health →
Sponsor
University of Florida
Who can join
Adults 40 to 67, female only, with Skin Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this clinical trial is to determine the activity of dealcoholized muscadine wine to alleviate oxidative stress, inflammation, skin photoaging, and alter gut microbiome in women 40-67 years of age. The investigators hypothesize that dealcoholized muscadine wine daily for 42 days will significantly alleviate oxidative stress, inflammation, skin photoaging, and alter the gut microbiome in women compared to drinking sugar water.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Measurement of Transepidermal Water Loss.
Kundu D, Jayaraman A, Sen CK. · · 2026 · cited 4× · PMID 40476522 · DOI 10.1089/wound.2024.0148
Verify or expand the search:
- PubMed search for NCT04614753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Health
Currently open trials in the same condition.
- NCT07383974 — The Impact of 12 Week Retention of Nutrients on Skin and the Perception of Physical Health Status · NA · recruiting
- NCT07215689 — Effects of KSM-66 Ashwagandha® (300 mg) on Skin and Hair Health in Healthy Men and Women" · NA · recruiting
- NCT07133477 — A Study to Evaluate the Effect of Fish Oil Concentrate on Skin Function · NA · recruiting
- NCT06952959 — The Effects of Cosmetic Acupuncture · NA · recruiting
Other University of Florida trials
Trials by the same sponsor.
- NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
- NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
- NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
- NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
- NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04614753 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florida
- Last refreshed: 12 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04614753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing